Fetal renal stem cell transplant in nephrotic and nonnephrotic glomerulonephritis with stage 2-4 chronic kidney disease

Potential effect on proteinuria and glomerular filtration rate

Saltanat Tuganbekova, Abduzhappar Gaipov, Zaiyrkhan Turebekov, Samat Saparbayev, Galiya Shaimardanova, Nadezhda Popova, Zhannat Taubaldiyeva, Dina Serebrennikova, Rakhat Trimova

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Proteinuria is a major cause of glomerulosclerosis progression in glomerular diseases, and the development of end-stage renal disease is more rapid in nephrotic patients than in nonnephrotic ones. The renal parenchyma is less regenerable because it is a tissue consisting of renal cells. Thus, stem cells obtained from fetal kidney tissue might be effective for reducing proteinuria and delaying glomerulosclerosis in these patients. Materials and Methods: This report presents preliminary data from a prospective cohort study that included 17 patients with chronic glomerulonephritis in stage 2 to 4 chronic kidney disease who completed 3 visits during 1 year of follow-up. Fetal renal stem cells (multiple cells in suspension) were injected into the patient every 6 months. Patients were divided into 2 groups according to their nephrotic status, and 24-hour maximal proteinuria was recorded for at least 6 months (first group with proteinuria < 3.5 g/24 h, and second group with proteinuria > 3.5 g/24 h). Results: During follow-up, group 1 was observed to have stable hemoglobin and total protein levels but significantly decreased albumin levels and glomerular filtration rates. In group 2, total protein with serum albumin significantly increased, and proteinuria and glomerular filtration rates sig - nificantly decreased. There was no significant difference in glomerular filtration rate decline between groups. Conclusions: Treatment with fetal renal stem cells significantly decreased proteinuria in nephrotic patients. However, this outcome also might have resulted from a reduction in glomerular filtration rate. Further studies with a larger number of patients and a control group would help to achieve better results that measure the efficacy of this treatment.

Original languageEnglish (US)
Pages (from-to)156-159
Number of pages4
JournalExperimental and Clinical Transplantation
Volume13
DOIs
StatePublished - Nov 1 2015

Fingerprint

Fetal Stem Cells
Glomerulonephritis
Glomerular Filtration Rate
Chronic Renal Insufficiency
Proteinuria
Transplants
Kidney
Serum Albumin
Chronic Kidney Failure
Albumins
Suspensions
Hemoglobins
Proteins
Fetus
Cohort Studies
Stem Cells
Prospective Studies
Control Groups

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Fetal renal stem cell transplant in nephrotic and nonnephrotic glomerulonephritis with stage 2-4 chronic kidney disease : Potential effect on proteinuria and glomerular filtration rate. / Tuganbekova, Saltanat; Gaipov, Abduzhappar; Turebekov, Zaiyrkhan; Saparbayev, Samat; Shaimardanova, Galiya; Popova, Nadezhda; Taubaldiyeva, Zhannat; Serebrennikova, Dina; Trimova, Rakhat.

In: Experimental and Clinical Transplantation, Vol. 13, 01.11.2015, p. 156-159.

Research output: Contribution to journalArticle

Tuganbekova, Saltanat ; Gaipov, Abduzhappar ; Turebekov, Zaiyrkhan ; Saparbayev, Samat ; Shaimardanova, Galiya ; Popova, Nadezhda ; Taubaldiyeva, Zhannat ; Serebrennikova, Dina ; Trimova, Rakhat. / Fetal renal stem cell transplant in nephrotic and nonnephrotic glomerulonephritis with stage 2-4 chronic kidney disease : Potential effect on proteinuria and glomerular filtration rate. In: Experimental and Clinical Transplantation. 2015 ; Vol. 13. pp. 156-159.
@article{69d341031f6644d58edad2298f2038b3,
title = "Fetal renal stem cell transplant in nephrotic and nonnephrotic glomerulonephritis with stage 2-4 chronic kidney disease: Potential effect on proteinuria and glomerular filtration rate",
abstract = "Objectives: Proteinuria is a major cause of glomerulosclerosis progression in glomerular diseases, and the development of end-stage renal disease is more rapid in nephrotic patients than in nonnephrotic ones. The renal parenchyma is less regenerable because it is a tissue consisting of renal cells. Thus, stem cells obtained from fetal kidney tissue might be effective for reducing proteinuria and delaying glomerulosclerosis in these patients. Materials and Methods: This report presents preliminary data from a prospective cohort study that included 17 patients with chronic glomerulonephritis in stage 2 to 4 chronic kidney disease who completed 3 visits during 1 year of follow-up. Fetal renal stem cells (multiple cells in suspension) were injected into the patient every 6 months. Patients were divided into 2 groups according to their nephrotic status, and 24-hour maximal proteinuria was recorded for at least 6 months (first group with proteinuria < 3.5 g/24 h, and second group with proteinuria > 3.5 g/24 h). Results: During follow-up, group 1 was observed to have stable hemoglobin and total protein levels but significantly decreased albumin levels and glomerular filtration rates. In group 2, total protein with serum albumin significantly increased, and proteinuria and glomerular filtration rates sig - nificantly decreased. There was no significant difference in glomerular filtration rate decline between groups. Conclusions: Treatment with fetal renal stem cells significantly decreased proteinuria in nephrotic patients. However, this outcome also might have resulted from a reduction in glomerular filtration rate. Further studies with a larger number of patients and a control group would help to achieve better results that measure the efficacy of this treatment.",
author = "Saltanat Tuganbekova and Abduzhappar Gaipov and Zaiyrkhan Turebekov and Samat Saparbayev and Galiya Shaimardanova and Nadezhda Popova and Zhannat Taubaldiyeva and Dina Serebrennikova and Rakhat Trimova",
year = "2015",
month = "11",
day = "1",
doi = "10.6002/ect.tdtd2015.P88",
language = "English (US)",
volume = "13",
pages = "156--159",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",

}

TY - JOUR

T1 - Fetal renal stem cell transplant in nephrotic and nonnephrotic glomerulonephritis with stage 2-4 chronic kidney disease

T2 - Potential effect on proteinuria and glomerular filtration rate

AU - Tuganbekova, Saltanat

AU - Gaipov, Abduzhappar

AU - Turebekov, Zaiyrkhan

AU - Saparbayev, Samat

AU - Shaimardanova, Galiya

AU - Popova, Nadezhda

AU - Taubaldiyeva, Zhannat

AU - Serebrennikova, Dina

AU - Trimova, Rakhat

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objectives: Proteinuria is a major cause of glomerulosclerosis progression in glomerular diseases, and the development of end-stage renal disease is more rapid in nephrotic patients than in nonnephrotic ones. The renal parenchyma is less regenerable because it is a tissue consisting of renal cells. Thus, stem cells obtained from fetal kidney tissue might be effective for reducing proteinuria and delaying glomerulosclerosis in these patients. Materials and Methods: This report presents preliminary data from a prospective cohort study that included 17 patients with chronic glomerulonephritis in stage 2 to 4 chronic kidney disease who completed 3 visits during 1 year of follow-up. Fetal renal stem cells (multiple cells in suspension) were injected into the patient every 6 months. Patients were divided into 2 groups according to their nephrotic status, and 24-hour maximal proteinuria was recorded for at least 6 months (first group with proteinuria < 3.5 g/24 h, and second group with proteinuria > 3.5 g/24 h). Results: During follow-up, group 1 was observed to have stable hemoglobin and total protein levels but significantly decreased albumin levels and glomerular filtration rates. In group 2, total protein with serum albumin significantly increased, and proteinuria and glomerular filtration rates sig - nificantly decreased. There was no significant difference in glomerular filtration rate decline between groups. Conclusions: Treatment with fetal renal stem cells significantly decreased proteinuria in nephrotic patients. However, this outcome also might have resulted from a reduction in glomerular filtration rate. Further studies with a larger number of patients and a control group would help to achieve better results that measure the efficacy of this treatment.

AB - Objectives: Proteinuria is a major cause of glomerulosclerosis progression in glomerular diseases, and the development of end-stage renal disease is more rapid in nephrotic patients than in nonnephrotic ones. The renal parenchyma is less regenerable because it is a tissue consisting of renal cells. Thus, stem cells obtained from fetal kidney tissue might be effective for reducing proteinuria and delaying glomerulosclerosis in these patients. Materials and Methods: This report presents preliminary data from a prospective cohort study that included 17 patients with chronic glomerulonephritis in stage 2 to 4 chronic kidney disease who completed 3 visits during 1 year of follow-up. Fetal renal stem cells (multiple cells in suspension) were injected into the patient every 6 months. Patients were divided into 2 groups according to their nephrotic status, and 24-hour maximal proteinuria was recorded for at least 6 months (first group with proteinuria < 3.5 g/24 h, and second group with proteinuria > 3.5 g/24 h). Results: During follow-up, group 1 was observed to have stable hemoglobin and total protein levels but significantly decreased albumin levels and glomerular filtration rates. In group 2, total protein with serum albumin significantly increased, and proteinuria and glomerular filtration rates sig - nificantly decreased. There was no significant difference in glomerular filtration rate decline between groups. Conclusions: Treatment with fetal renal stem cells significantly decreased proteinuria in nephrotic patients. However, this outcome also might have resulted from a reduction in glomerular filtration rate. Further studies with a larger number of patients and a control group would help to achieve better results that measure the efficacy of this treatment.

UR - http://www.scopus.com/inward/record.url?scp=84953849172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953849172&partnerID=8YFLogxK

U2 - 10.6002/ect.tdtd2015.P88

DO - 10.6002/ect.tdtd2015.P88

M3 - Article

VL - 13

SP - 156

EP - 159

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

ER -